In The News: Department of Brain Health
A new family of drugs works to rid Alzheimer’s Disease patients’ brains of the proteins believed to be behind the memory-robbing illness.
The new report, published in the peer-reviewed academic journal Alzheimer’s Research & Therapy, involved medical experts and researchers in dementia from the National Institutes of Health in Baltimore, the Icahn School of Medicine at Mount Sinai in New York, the University of Nevada in Las Vegas, and the Medical University of South Carolina in Charleston, S.C.
GLP-1s have been a breakthrough for obesity and diabetes. A 2022 study examined data from trials of GLP-1s in nearly 16,000 patients with diabetes, and showed that the drugs were associated with a 53% reduction in dementia risk.
More than 250 representatives are coming together to not only network but also share their dedication to find the cure for Alzheimer's. This includes announcing a new partnership with UNLV.
More than 250 representatives are coming together to not only network but also share their dedication to find the cure for Alzheimer's. This includes announcing a new partnership with UNLV.
A blood test for Alzheimer’s Disease a game-changer for patients and their families.
A blood test for Alzheimer’s Disease a game-changer for patients and their families.
As current drugs fall short, companies are exploring new targets to treat the neurodegenerative disease
For decades, diagnosing Alzheimer’s disease (AD) has required access to specialist memory clinics, neuroimaging or invasive cerebrospinal fluid (CSF) testing. That paradigm is starting to shift. In 2025, the US Food and Drug Administration (FDA) cleared the first blood-based biomarker tests intended to aid the assessment of AD.
A new Nevada law prohibits schools from using AI to perform the work of school counselors and other professionals involved in the mental health of students. We discuss the pros and cons of using AI in mental health work, and we meet the humanoid robots creators say can serve as companions. Then, a discussion on reducing Alzheimer’s disease risks in Your Brain Health Matters.
Today, Global Alzheimer’s Platform Foundation® (GAP) and Clinical Neurology Specialists (CNS) announced their collaboration to accelerate Alzheimer’s disease research in Las Vegas. CNS has joined the GAP-sponsored study, Bio-Hermes-002, a unique, observational platform study that compares blood-based and digital biomarkers to generate data that may help predict, detect and diagnose Alzheimer’s disease and related dementias. This is a transformative, international study, but CNS is the only Las Vegas research site participating.
A study on Ozempic’s impacts on Alzheimer’s disease didn’t have the results scientists hoped for. We talk to UNLV’s Dr. Jeffrey Cummings on the research and what’s next. Also from UNLV: a look at how a “new” species of an ancient human ancestor can help shape our view on evolution. We end with a fun story on “Silver Belle”... the first tree from Nevada to serve as the U.S. Capitol Christmas Tree!
